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Background: Polo-like kinase 1 (PLK1) is highly expressed in many human cancers and regulates critical steps in
mitotic progression. Previously, we have reported that PLK1 was overexpressed in non-small cell lung cancer (NSCLC),
but the underlying molecular mechanisms are not well understood. By using microRNA (miR) target prediction
algorithms, we identified miR-100 that might potentially bind the 3’-untranslated region of PLK1 transcripts. The
purpose of this study was to investigate the roles of miR-100 and its association with PLK1 in NSCLC development.
Methods: Taqman real-time quantitative RT-PCR assay was performed to detect miR-100 expression 10 NSCLC tissues
and corresponding nontumor tissues. Additionally, the expression of miR-100 in 110 NSCLC tissues and its correlation
with clinicopathological factors or prognosis of patients was analyzed. Finally, the effects of miR-100 expression on
growth, apoptosis and cell cycle of NSCLC cells by posttranscriptionally regulating PLK1 expression were determined.
Results: MiR-100 was significantly downregulated in NSCLC tissues, and low miR-100 expression was found to be
closely correlated with higher clinical stage, advanced tumor classification and lymph node metastasis of patients. The
overall survival of NSCLC patients with low miR-100 was significantly lower than that of those patients with high miR-
100, and univariate and multivariate analyses indicated that low miR-100 expression might be a poor prognostic factor.
Also, miR-100 mimics could lead to growth inhibition, G2/M cell cycle arrest and apoptosis enhancement in NSCLC
cells. Meanwhile, miR-100 mimics could significantly inhibit PLK1 mRNA and protein expression and reduce the
luciferase activity of a PLK1 3’ untranslated region-based reporter construct in A549 cells. Furthermore, small interfering
RNA (siRNA)-mediated PLK1 downregulation could mimic the effects of miR-100 mimics while PLK1 overexpression
could partially rescue the phenotypical changes of NSCLC cells induced by miR-100 mimics.
Conclusions: Our findings indicate that low miR-100 may be a poor prognostic factor for NSCLC patients and
functions as a tumor suppressor by posttranscriptionally regulating PLK1 expression.Background
Lung cancer is the leading cause of cancer-related deaths
around the world, among both men and women, with an
incidence of over 200000 new cases per year and a very
high mortality rate [1]. Approximately 85% of all lung
cancer cases are categorized as non-small cell lung can-
cer (NSCLC). Despite much progress in early detection
and treatment, the 5-year survival rate for NSCLC* Correspondence: wangzhaox@yahoo.com.cn
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reproduction in any medium, provided the orpatients at later stages is only 5-20% [2]. Thus, a better
understanding of the molecular mechanisms underlying
NSCLC progression and development will be helpful for
improvement of current therapeutics and the identifica-
tion of novel targets.
PLK1 belongs to a family of conserved serine/threonine
kinases that are involved in cell-cycle progression and
various mitotic stages [3]. The overexpression of PLK1
has been reported to play critical roles in malignant
transformation and tumor development [4,5]. It has
been found that PLK1 is overexpressed in a variety of
human tumours and has prognostic potential in cancer,
indicating its involvement in carcinogenesis and its po-
tential as a therapeutic target [6]. Although Wolf and hisThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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new independent prognostic indicator for patients with
NSCLC [7], the clinical significance of PLK1 protein in
NSCLC was unclear. In our previous study, we have
shown that high PLK1 protein expression was signifi-
cantly correlated with higher clinical stage, advanced
tumor classification and lymph node metastasis of
NSCLC patients and might be a poor prognostic mo-
lecular marker [8]. Meanwhile, we also found that RNA
interference-mediated PLK1 downregulation could in-
hibit in vitro and in vivo proliferation, induce cell arrest
of G2/M phase, increase apoptosis and enhance chemo-or
radiosensitivity of NSCLC cells. In addition, Spänkuch-
Schmitt B’ et al. reported that downregulation of human
polo-like kinase activity by antisense oligonucleotides
induced growth inhibition in cancer cells including
NSCLC cell line (A549) [9]. This research group also
found that PLK1 function appeared to be essential for
centrosome-mediated microtubule events and, conse-
quently, for spindle assembly and siRNAs targeted against
human PLK1 might be valuable tools as antiproliferative
agents against a broad spectrum of neoplastic cells includ-
ing NSCLC cell line (A549) [10]. Raab and his colleagues
found that the primary cells’proliferation, spindle assembly
and apoptosis exhibited only a low dependency on Plk1 in
contrast to the addiction of many cancer cell lines to the
non-oncogene Plk1 [11]. Also, Liu and colleagues showed
that normal cells but not cancer cells could survive severe
Plk1 depletion [12]. These data further support sugges-
tions that Plk1 might be a feasible cancer therapy target.
However, the molecular mechanisms of PLK1 upregula-
tion in NSCLC are still unclear. MicroRNAs are a class of
single-stranded RNA molecules of 21–23 base pair in
length and regulate target genes expression through spe-
cific base-pairing interactions between miRNA and un-
translated regions of targeted mRNAs [13]. miRNAs can
bind to the 3’-untranslated regions (UTRs) of target
mRNAs, which leads to mRNA degradation or repression
of mRNA translation. It has been reported that approxi-
mately > 30% of protein-coding genes can be directly
modulated by miRNAs [14]. Other groups have shown
that underexpressed miR-100 leads to Plk1 overexpres-
sion, which in turn contributes to nasopharyngeal cancer
progression [15]. It was also reported that miR-100 could
affect the growth of epithelial ovarian cancer cells by post-
transcriptionally regulating polo-like kinase 1 expression
[16]. However, the status of miR-100 expression in NSCLC
is unclear, and whether miR-100 plays a critical role in
NSCLC development by posttranscriptionally regulating
PLK1 expression needs to be further elucidated.
In the present study, we set out to detect the expres-
sion of miR-100 in NSCLC tissues and analyze its correl-
ation with clinicopathological factors or prognosis of
NSCLC patients, and post-transcriptional regulatoryrelation between miR-100 and PLK1 in NSCLC cells,
which will provide one day a potential molecular thera-
peutic target for human NSCLCs.
Methods
Sample population
A total of 112 primary NSCLCs were collected from the
Department of Cardiothoracic Surgery, Nanjing Medical
University between 2003 and 2006. All patients gave writ-
ten informed consent. The study was approved by the
Ethic Committee of Second Affiliated Hospital, Nanjing
Medical University and it was performed in compliance
with the Helsinki Declaration. All patients did not receive
chemotherapy or radiotherapy prior to surgery. Patient
characteristics are shown in Additional file 1 Table S1.
Disease histology was determined in accordance to the cri-
teria of the World Health Organization. Pathologic staging
was performed in accordance to the current International
Union Against Cancer tumor-lymph node-metastasis
classification. 10 randomly selected NSCLC tumors and
their matched histologically normal lung parenchyma
adjacent to the tumors (within 1 cm of the discrete tumor
margin) were immediately frozen in liquid nitrogen and
stored at −70°C until use. All tissue samples were snap-
frozen in liquid nitrogen, which were transferred to 500
ml TRIzol solution (Invitrogen, CA, USA) immediately
after harvesting in order to avoid mRNA degradation.
Cell line and cell culture conditions
NSCLC cell line (A549) was cultured in Dulbecco’s modi-
fied Eagle’s medium (Invitrogen, Carlsbad, CA) supple-
mented with 10% fetal bovine serum, 100 U/ml penicillin
and 100 μg/ml streptomycin. Cell cultures were incubated
in a humidified atmosphere of 5% CO2 at 37°C.
Construction of plasmid vectors
Previously, the pcDNA/PLK1 vector with the PLK1 cod-
ing region was successfully constructed and conserved
by our lab. To construct a luciferase reporter vector, the
PLK1 3’-UTR fragment containing putative binding sites
for miR-100 was amplified by PCR using the following
primers: sense 5’-CCATACTGGTTGGCTCCCGCGG-3’
and reverse 5’-ATGTGCATAAAGCCAAGGAAAGG-3’,
and inserted into downstream of the luciferase gene in
the pLuc luciferase vector (Ambion, USA) and named
PLK1 3’-UTR-wild. Site-directed mutagenesis of the
miR-100 target-site in the PLK1-3’-UTR was performed
using the Quick-change mutagenesis kit (Stratagene,
Heidelberg, Germany) and named PLK1 3’-UTR-mut
according to the manufacturer’s instructions.
Transfection of miR-100 mimics or inhibitor
MiR-100 mimics (or anti-miR-100) and their negative
control oligonucleotides (miR-NC or anti-miR-100) were
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PLK1 (5’-AAGGGCGGCUUUGCCAAGUGC-3’) and its
negative control oligonucleotide (siRNA/NC: 5’-AAUUUG
GCCGGGCCGUGCG-3’) were purchased from Santa
Cruze Inc (CA, USA). The transfection were performed
using Lipofectamine™ 2000 (Invitrogen, USA) according to
the instructions provided by the manufacturer. The trans-
ected cells were resuspended and cultured in regular
culture medium for 48-72 h before analysis.
TaqMan RT-PCR for miRNA quantification
Total RNA was isolated from the cell lines with Trizol™
(Invitrogen, USA), reverse transcribed using Taqman™
microRNA reverse transcription kit and subjected to
real-time PCR using TaqMan™ MicroRNA Assay kit
(Applied Biosystems, USA) according to the manufac-
turer’s instructions. Reactions were performed using
Stratagene Mx3000 instrument in triplicate. MiRNA ex-
pression was normalized to U6.
Semi-quantitative RT-PCR assay
Total RNA isolated from cells or tissues using an RNeasy
Mini Kit (Qiagen, USA) was reverse-transcribed with ran-
dom hexamers and a Transcriptor First Strand cDNA
Synthesis Kit (TaKaRa, Dalian, China). The GAPDH pri-
mers were as follows: sense: 5’-CACCATCTTCCAGG-A
GCGAG-3’, reverse: 5’-TCACGCCACAGTTTCCCGGA-3’
(372 bp). Equal cDNA amounts from each sample were
amplified using the following primers to detect PLK1 ex-
pression: sense, 5’-TTCGTGTTCGTGGTGTTGGA-3’; re-
verse, 5’-CTCGTCATTAAGCAGCTCGT-3’ (563 bp).
Thermal cycles were: 1 cycle of 94°C for 3 min; 30 cycles
of 94°C for 40s, 56°C for 40s, 68°C for 90s; followed by
72°C for 10 min. RT-PCR products were electrophoresed
in a 1.5% agarose gel with ethidium bromide staining.
Western blot assay
Proteins were isolated and separated by 7.5% SDS–PAGE
and electrotransferred to polyvinylidene fluoride mem-
branes. Residual binding sites on the membrane were
blocked in 5% skim milk for 1 h at room temperature.
The blots were incubated with primary antibodies against
human PLK1 (Santa Cruz, CA, USA) at 1:500 overnight
at 4°C and then with anti-rabbit IgG (horseradish
peroxidase-conjugated secondary antibody) for 1 h at
room temperature. After washing, the membranes were




The transfected cells (A549) were seeded into 96-well
culture plates. After overnight incubation, cells treated
with various concentrations of chemotherapeutic drugs.Following incubation for 24 h, cell growth was measured
following addition of 0.5 mg/ml 3-(4,5-dimethyl-thia-zol-
2-yl)-2,5-diphenyltetrazoliumbromide (MTT, Sigma) solu-
tion. About 4 h later, the medium was replaced with
100 μL dimethylsulfoxide (DMSO, Sigma) and vortexed
for 10 min. Absorbance (A) was then recorded at 490 nm
using a microplate reader (Bio-Rad, USA).
Hoechst staining assay
Cells were cultured in 6 well plates to confluence and
Hoechst 33342 (Sigma, USA) was then added. Nuclear
morphology changes were detected by fluorescence mi-
croscopy using a filter for Hoechst 33342 (365 nm). The
percentages of Hoechst-positive nuclei per optical field
(≥ 50 fields) were counted.
Flow cytometric analysis of cell cycle
Cells were harvested at 70% confluence and fixed in 70%
ethanol at −20°C. After a PBS wash, cells were treated
with RNase A at 37°C for 30 min. After centrifugation,
cells were resuspended in propidium iodide (PI) (50 μg/ml)
for 30 min at room temperature. DNA content was
then evaluated using a FACScan flow cytometer (Becton
Dickinson, Mountain View, CA).
Luciferase assay
The constructs were sequenced and named pLuc-PLK1-wt
or pLuc-PLK1-mut. For reporter assays, A549 cells
were cultured in 24-well plates and each transfected with
100 ng of pLuc-PLK1-wt or pLuc-PLK1-mut and 50 nM of
miR-100 mimics or anti-miR-100 using Lipofectamine
2000 (Invitrogen, USA). Forty eight hours after transfection,
cells were harvested and assayed with Dual-Luciferase
Reporter Assay kit (Promega, USA) according to the manu-
facturer’s instructions.
Statistical analysis
Data are presented as mean ± SD. For comparison of
means between two groups, a two-tailed t-test was
used, and for comparison of means among three
groups, one-way ANOVA was used The Spearman correl-
ation test was used for analyses of primary tumors. Sur-
vival probabilities were determined using Kaplan-Meier
analysis and the significance of difference was analyzed by
a log-rank test. Significance was accepted at P < 0.05.
Results
MiR-100 was significantly downregulated in NSCLC
tissues compared with corresponding nontumor tissues
Real-time quantitative RT-PCR assay was performed to
detect the expression of miR-100 in 10 NSCLC tissues
and corresponding nontumor tissues. As shown in
Figure 1A, the relative level of miR-100 expression was sig-
nificantly lower in NSCLC tissues than in corresponding
Liu et al. BMC Cancer 2012, 12:519 Page 4 of 11
http://www.biomedcentral.com/1471-2407/12/519nontumor tissues. The mean miR-100 expression level
(△Ct) was −4.527 ± 1.04 for NSCLC tissues (n = 10)
and −9.878 ± 1.33 for corresponding nontumor tissues
(n = 10); this difference was statistically significant with a
P-value of <0.01 (Figure 1B). Thus, it was concluded that
downregulation of miR-100 might play important roles in
lung tumorigenesis.
Association of miR-100 expression with
clinicopathological features of NSCLC patients
Real-time quantitative RT-PCR assay was performed to
detect the expression of miR-100 in 110 NSCLC tissues,
and the association of miR-100 expression with clinico-
pathological features of NSCLC patients was performed
(Additional file 1 Table S1). The mean miR-100 expression
level (△Ct) was −6.218 ± 1.53 for NSCLC tissue (n = 110).
Patients with miR-100 expression (△Ct < −6.218) were
considered as the low expression group (n = 64), while
patients with miR-100 expression (△Ct ≥ −6.218) were
considered as the high expression group (n = 46). By stat-
istical analyses, we showed that low miR-100 expres-
sion was closely correlated with higher clinical stage,
advanced tumor classification and lymph node metas-
tasis (P = 0.005, 0.013 and 0.001, respectively).Figure 1 Taqman real-time quantitative analysis of miR-100
expression in tissue samples. (A) Determining the ΔCt values of
miR-100 in 10 cases of NSCLC tissues and corresponding nontumor
tissues. (B) Comparison of mean ΔCt of miR-100 between 10 cases
of NSCLC tissues (−4.527 ± 1.04) and corresponding nontumor
tissues (−9.878 ± 1.33; P < 0.01). The mean and standard deviation of
expression levels relative to U6 expression levels are shown and are
normalized to the expression in the normal tissue of each matched
pair. All experiments were performed at least in triplicate.
Corresponding P values analyzed by t-tests are indicated.However, the expression of miR-100 was not correlated
with other factors of patients including sex, age, smoking,
histological type (P = 0.488, 0.583, 0.359 and 0.871, re-
spectively). These data showed that low miR-100 expres-
sion might play important roles in NSCLC development.Association of miR-100 with prognosis of NSCLC patients
The association of miR-100 expression with prognosis of
NSCLC patients was also investigated by Kaplan-Meier
analysis and log-rank test. As shown in Figure 2A, there
was no significant difference in 5-year disease-free
survival (DFS) between patients with low miR-100 ex-
pression and those with high miR-100 expression
(P = 0.078). However, the 5-year overall survival (OS) of
patients with high miR-100 expression was significantly
higher than that of those with low miR-100 expression
(P = 0.006; Figure 2B). Univariate analysis showed that
clinical stage, lymph node metastasis and low miR-100
expression were significantly correlated with poor over
survival of NSCLC patients (P = 0.003, 0.016 and 0.022,
respectively; Table 1). Multivariate analysis using the Cox
proportional hazard model indicated that the status of
lymph node metastasis and the level of miR-100 expres-
sion were independent prognostic factors for NSCLC
patients (P = 0.036 and 0.008, respectively; Table 1).
Thus, miR-100 expression could affect the prognosis of
NSCLC patients, and low miR-100 expression might be a
poor prognostic factor.Figure 2 Kaplan-Meier survival curves of NSCLC patients.
Kaplan-Meier survival curves for NSCLC patients based on the
median level of fold change. The P-value was calculated using the
log-rank test between patients with high- and low-fold changes.
Disease-free or overall survival of patients with high vs. low miR-100
expression levels are shown. (A) The 5-year disease-free survival rate
showed no difference between NSCLC patients with high miR-100
and those with low miR-100 (P = 0.078). (B) The 5-year overall
survival rate of NSCLC patients with high miR-100 was significantly
higher than that of those patients with low miR-100 (P = 0.006).
P < 0.05 indicates a significant difference between groups.
Corresponding P values analyzed by log-rank tests are indicated.
Table 1 Univariate and multivariate analysis of prognostic factors by Cox regression analysis
Clinicopathological features Univariate analysis Multivariate analysis
RR (95% CI) P-value RR (95% CI) P-value
Male (Male / female) 2.27 (0.87-3.11) 0.108 1.99 (0.67-2.63) 0.112
Age (year) (>60 / ≤60) 1.42 (0.92-1.79) 0.321 2.56 (0.89-3.12) 0.304
Smoking (Smoker / Nonsmoker) 1.65 (0.58-1.88) 0.084 2.13 (0.75-2.70) 0.156
Histological type (SCC / AD) 2.08 (0.39-2.75) 0.202 0.87 (0.46-1.68) 0.286
Clinical stage (III / I + II) 2.76 (1.23-3.82) 0.003 3.13 (0.95-4.03) 0.067
Tumor classification (T3+4 / T1+2) 0.98 (0.44-1.55) 0.215 1.53 (0.74-1.88) 0.082
Lymph node metastasis (N1+2 / N0) 3.12 (2.03-4.12) 0.016 1.65 (1.12-3.58) 0.036
miR-100 expression (Low / High) 1.74 (1.04-2.36) 0.022 2.44 (1.89-2.95) 0.008
RR: relative ratio; 95% CI: 95% confidence interval.
SCC: squamous cell carcinoma; AD: adenocarcinoma.
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cell cycle of NSCLC cells
Next, the effects of miR-100 expression on malignant
phenotypes of NSCLC cells were investigated. 48 h after
transfection with miR-100/mimics (or miR-NC/mimics)
or anti-miR-100 (or anti-miR-NC), Real-time quantitative
RT-PCR assay was performed to detect the expression of
miR-100 in A549 cells. As shown in Figure 3A, the level of
miR-100 expression in A549/miR-100 cells was signifi-
cantly increased by approximately 586.7% compared with
A549/miR-NC cells (P < 0.01). Compared with that in
A549/anti-miR-100 cells, the level of miR-100 expression
in A549/anti-miR-100 cells was also significantly
decreased by approximately 54.3% (P < 0.05). The results
of MTT assay showed that miR-100 mimics could mark-
edly inhibit the growth of A549 cells while miR-100 inhi-
bitors could slightly promote the growth of A549 cells
(Figure 3B). Then, we analyzed the effect of miR-100 ex-
pression on apoptosis of NSCLC cells (Figure 3C). The
results of Hoechst staining assay showed that the apop-
totic rate of A549/miR-100 cells was significantly
increased by 18.3 ± 1.4% compared with A549/miR-NC
cells (P < 0.01). However, the apoptotic rate of A549/anti-
miR-100 cells showed no significance changes compared
with that of A549/anti-miR-NC cells (P > 0.05). Next, the
effect of miR-100 expression on cell cycle of A549 cells
was also determined by flow cytometry (Figure 3D). Com-
pared with A549/miR-NC cells, A549/miR-100 cells
showed the increased percentage of apoptotic cells
(SubG1) and G2/M stage cells and the decreased percent-
age of G0/G1 stage cells (P < 0.05). However, the percent-
age of S stage cells showed no difference between those
two transfected A549 cells. Compared with A549/anti-
miR-NC cells, A549/anti-miR-100 cells showed the
decreased percentage of G2/M stage cells and the
increased percentage of G0/G1 stage cells (P < 0.05). Like-
wise, the percentage of S stage cells showed no difference
between A549/anti-miR-NC and A549/anti-miR-100 cells.
From these data, it was concluded that miR-100 couldinhibit growth of NSCLC cells by modulating apoptosis
and cell-cycle distribution.PLK1 is a functional target of miR-100 in NSCLC
It has been reported that miRNAs can function post-
transcriptionally by reducing protein yield from specific
target mRNAs. To identify miR-100 targets, we performed
in-silico screening using TargetScan with a recently
described strategy [17]. We found that, among the pre-
dicted miR-100 target genes, the 3’-UTR of PLK1 gene
contained binding sites for miR-100 with reasonable
scores. In other cancers, PLK1 has been reported to be a
functional target of miR-100. Sequence analyses revealed
that the 3’-UTR of PLK1 mRNA contains a putative site
partially complementary to miR-100 (Figure 4A). To ex-
perimentally validate whether PLK1 is a possible target of
miR-100 in NSCLC, we detected the expression of PLK1
mRNA and protein in miR-100 mimics or anti-miR-100-
transfected A549 cells. RT-PCR and Western Blot assays
showed that the expression levels of PLK1 both mRNA
and protein were significantly downregulated by miR-100
mimics while miR-100 inhibitors could increase the ex-
pression levels of PLK1 mRNA and protein in A549 cells
(Figure 4B). To further determine whether PLK1 was a
bona fide target of miR-100-mediated gene overex-
pression, the entire 3’-UTR of PLK1 mRNA and the
miR-100 binding region within 3’-UTR of PLK1
mRNA were cloned into a luciferase reporter. As
shown in Figure 4C, upregulation of miR-100 could
result in a significant decrease in luciferase activity
when the reporter contained a wild-type sequence
(WT), but not when it contained a mutant sequence
(MT) within the miR-100 binding site (five nucleo-
tides within the complementary seed sequence).
Meanwhile, downregulation of miR-100 could lead to
a significant increase in luciferase activity the reporter
contained a wild-type sequence (WT), but not when
it contained a mutant sequence (MT) within the miR-
Figure 3 Effects of miR-100 mimics or inhibitor on growth, apoptosis and cell cycle of NSCLC cells. (A) 48h after A549 cells were
transfected with miR-100 mimics (or miR-NC mimics) or anti-miR-100 (or anti-miR-NC), Taqman real-time quantitative RT-PCR analysis of miR-100
expression. (B) MTT analysis of growth in A549/miR-100 (or A549/miR-NC) or A549/anti-miR-100 (or A549/anti-miR-NC) cells. (C) Hoechst staining
analysis of apoptosis in A549/miR-100 (or A549/miR-NC) or A549/anti-miR-100 (or A549/anti-miR-NC) cells. Fragmentation of the nucleus into
oligonucleosomes and chromatin condensation were examined by fluorescence microscopy. The percentage of Hoechst-positive nuclei per
optical field (at least 50 fields) was counted. (D) Flow cytometric analysis of cell cycle distribution in A549/miR-100 (or A549/miR-NC) or A549/anti-
miR-100 (or A549/anti-miR-NC) cells. * and ** indicate P < 0.05 and P < 0.01, respectively. Each experiment was performed at least in triplicate.
Corresponding P values analyzed by t-tests are indicated.
Liu et al. BMC Cancer 2012, 12:519 Page 6 of 11
http://www.biomedcentral.com/1471-2407/12/519100 binding site. Taken together, these data indicate
that miR-100 directly targets PLK1 in NSCLC cells.
Effects of siRNA-mediated PLK1 inhibition on malignant
phenotypes of NSCLC cells
\Next, siRNA targeting PLK1 was used to downregulate
PLK1 expression and analyze its effects on phenotypes of
NSCLC cells including growth, apoptosis and cell cycle.
As shown in Figure 5A, the expression levels of PLK1
mRNA and protein were significantly downregulated in
A549-siRNA/PLK1 cells compared with A549-siRNA/
control cells. MTT assay indicated that the growth rate of
A549-siRNA/PLK1 cells was significantly lower than that
of A549-siRNA/control cells (Figure 5B). Hoechst staining
assay showed that the apoptotic rate of A549-siRNA/
PLK1 cells was significantly increased by approximately
12.3% compared with that of A549-siRNA/control cells(Figure 5C). Finally, flow cytormetric analysis of cell cycle
showed that A549-siRNA/PLK1 cells showed the
increased percentage of apoptotic cells and G2/M stage
cells and the decreased percentage of G0/G1 stage cells
compared with A549-siRNA/control cells (Figure 5D).
Therefore, siRNA-mediated downregulation of PLK1
could mimic the effects of increased miR-100 in NSCLC
cells.
Overexpression of PLK1 could rescue the effects of
ectopic miR-100 expression in NSCLC cells
48h after pcDNA/PLK1 or pcDNA/control vector was
transfected into A549/miR-100 cells, the expression
levels of PLK1 mRNA and protein were determined. As
shown in Figure 6A, pcDNA/PLK1 could rescue the
decreased mRNA and protein expression in A549/miR-
100 cells. Also, pcDNA/PLK1 could partially reverse
Figure 4 PLK1 is a direct target of miR-100. (A) Alignment between the predicted miR-100 target sites and miR-100 is shown. (B) RT-PCR and
Western Blot assays were performed to detect the expression of PLK1 mRNA and protein expression in A549 cells transfected with miR-100
mimics (miR-NC mimics) or anti-miR-100 (anti-miR-NC). (C) A549 cells were co-transfected with miR-100 mimics or anti-miR-100 and pLUC vector
with PLK1 3’-UTR-wild or mut. After 24 hours, the luciferase activity was measured. Values are presented as relative luciferase activity after
normalization to Renilla luciferase activity. * and ** indicate P < 0.05 and P < 0.01, respectively. The data are expressed as the mean value ± SEM
of the results obtained from three independent experiments. Corresponding P values analyzed by t-tests are indicated.
Figure 5 Effects of siRNA targeting PLK1 on growth, apoptosis and cell cycle of NSCLC cells. (A) RT-PCR and Western Blot analysis of PLK1
mRNA and protein expression in A549-siRNA/PLK1 or A549-siRNA/control cells. (B) MTT analysis of growth in A549 cells at different time points
(0, 24, 48, 72 or 96h) after transfection with siRNA/PLK1 or siRNA/control. (C) Hoechst staining analysis of apoptosis in A549/miR-100 or A549/miR-
NC cells. The percentage of Hoechst-positive nuclei per optical field (at least 50 fields) was counted. (D) Flow cytometric analysis of cell cycle
distribution in A549-siRNA/PLK1 or A549-siRNA/control cells. * and ** indicate P < 0.05 and P < 0.01, respectively. Each experiment was performed
at least in triplicate. Corresponding P values analyzed by t-tests are indicated.
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Figure 6 DNA vector-mediated PLK1 overexpression could partially rescue the effects of miR-100 mimics on malignant phenotypes of
A549 cells. (A) RT-PCR and Western Blot analysis of PTEN mRNA and protein expression in A549/miR-NC, A549/miR-100 or A549/miR-100
co-transfected with pcDNA/control or pcDNA/PLK1. (B) MTT analysis of growth in A549/mi-NC, A549/miR-100 or A549/miR-100 co-transfected
with pcDNA/control or pcDNA/PLK1. (C) Hoechst staining analysis of apoptosis in A549/miR-NC, A549/miR-100 or A549/miR-100 co-transfected
with pcDNA/control or pcDNA/PLK1. The percentage of Hoechst-positive nuclei per optical field (at least 50 fields) was counted. (D) Flow
cytometric analysis of cell cycle distribution in A549/miR-NC, A549/miR-100 or A549/miR-100 co-transfected with pcDNA/control or pcDNA/PLK1.
* indicates P < 0.05. The data are expressed as the mean value ± SEM of the results obtained from three independent experiments. Corresponding
P values analyzed by ANNOVA tests are indicated.
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miR-100 cells (Figure 6B-C). Moreover, we found that
pcDNA/PLK1-mediated overexpression of PLK1 could
partially reverse the G2/M phase cell cycle arrest of
A549/miR-100 cells (Figure 6D). These results suggested
that overexpression of PLK1 could rescue the effects of
ectopic miR-100 on phenotypes of NSCLC cells.Figure 7 PLK1 was significantly upregulated in NSCLC tissues
and inversely correlated with miR-100 expression. (A) The
averaged mRNA level of PLK1 in NSCLC tissues (0.85 ± 0.15) was
significantly higher than that in corresponding nontumor tissues
(0.23 ± 0.06). GADPH was used as an internal control. (B) A
statistically significant inverse correlation between miR-100 and PLK1
mRNA levels in 20 cases of NSCLC tissues (Spearman’s correlation
analysis, r = −0.543; P < 0.001). Corresponding P values analyzed by a
t-test or Spearman correlation test are indicated.MiR-100 expression was inversely correlated with PLK1
mRNA expression in NSCLC tissues
Then, semi-quantitative RT-PCR assay was performed to
detect PLK1 mRNA expression in 10 NSCLC tissues and
corresponding nontumor tissues. As shown in Figure 7A,
the relative mRNA expression level of PLK1 in NSCLC
tissues (0.85 ± 0.15) was significantly higher than that in
corresponding nontumor tissues (0.23 ± 0.06; P < 0.05).
When the levels of PLK1 mRNA were plotted against
miR-100 expression, a significant inverse correlation was
observed (r = −0.543; P < 0.001; Figure 7B). Thus, these
data further support that downregulation of miR-100 was
inversely correlated with upregulation of PLK1 in
NSCLC tissues.Discussion
Previously, we have reported that PLK1 is overexpressed
in human NSCLC tissues and the overexpression of
PLK1 was correlated with poor prognosis and malignant
phenotypes of NSCLC patients. However, the molecular
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unclear. MiRNAs constitute a large family of small, ap-
proximately 21-nucleotide-long, non-coding RNAs that
have emerged as key post-transcriptional regulators of
gene expression, and miRNAs have been predicted to
control the activity of approximately 30% of all protein-
coding genes [18]. By base pairing to mRNAs, micro-
RNAs mediate translational repression or mRNA deg-
radation [19]. By performing in-silico screening using
TargetScan, we found that the 3’-UTR of PLK1 gene
contained binding sites for miR-100 with reasonable
scores. In the present study, we showed that downregu-
lation of miR-100 might play critical roles in the forma-
tion of malignant phenotypes by posttranscriptionally
regulating PLK1 expression.
Up to date, increasing evidence shows that the dysre-
gulation of miRNAs is correlated with tumor initiation
and progression, suggesting that miRNAs may act as
tumour suppressor genes or oncogenes [20,21]. Recent
studies have shown that not only can miRNAs be used
to sub-classify NSCLCs but specific miRNA profiles may
also predict prognosis and disease recurrence in early-
stage NSCLCs [22,23]. Since Takamizawa’ et al. firstly
reported that reduced expression of the let-7 micro-
RNAs in human lung cancers was found to be correlated
with shortened postoperative survival of patients [24],
other miRNAs were also found to be correlated with
prognosis of NSCLC patients [25,26]. In our previous
study, we also found that serum miR-21 expression
might be useful as a prognostic marker for NSCLC
patients [27]. With the development of research for ex-
periment, dysregulation of miRNAs were reported to
affect growth, apoptosis and chemo- or radioresistance
of NSCLC cells [28]. Xiong and his colleagues found that
microRNA-7 inhibited the growth of human non-small
cell lung cancer A549 cells through targeting BCL-2
[29]. Moreover, miRNA-145 was found to inhibit non-
small cell lung cancer cell proliferation by targeting c-
Myc [30]. In our previous studies, we have shown that
miR-451 functions as tumor suppressor in NSCLC by
targeting RAB14 gene [31]. Meanwhile, we also found
that the level of miR-451 could affect the sensitivity of
NSCLC cells to cisplatin [32]. In other researches, ec-
topic expression of miR-200c alters expression of EMT
proteins, sensitivity to erlotinib, and migration in lung
cells [33]. The association of dysregulated miRNAs with
angiogenesis and metastasis of NSCLC cells was
reported. Donnem and his colleagues showed that sev-
eral angiogenesis-related miRNAs (miR-21, miR-106a,
miR-126, miR-155, miR-182, miR-210 and miR-424.
miR-155) which were correlated significantly with fibro-
blast growth factor 2 (FGF2), are significantly altered in
NSCLC [34]. MicroRNA-328 along with other miRNAs
was found to be associated with (non-small) cell lungcancer (NSCLC) metastasis and mediates NSCLC migra-
tion [35]. Although miR-100 has been found to function
as a tumor suppressor in nasopharyngeal cancer, epithe-
lial ovarian cancer, bladder cancer and acute myeloid
leukemia [36,37], the expression of miR-100 and its roles
in NSCLC development are unknown.
In the present study, we firstly found that miR-100 was
significantly lower in NSCLC tissues than in corresponding
nontumor tissues. Then, we analyzed the association of
downregulated miR-100 with clinicopathologic factors of
NSCLC patients. By statistical analysis, we found that miR-
100 expression was significantly correlated with clinical
stage, tumor classification and lymph node metastasis of
NSCLC patients, suggesting that low miR-100 expression
might play roles in NSLC progression. The disease-free sur-
vival showed between NSCLC patients with low miR-100
and those with high miR-100, but the overall survival of
patients with high miR-100 was higher than that of patients
with low miR-100. Furthermore, multivariate analysis using
the Cox proportional hazard model indicated that miR-100
expression was an independent prognostic factor for
NSCLC patients. Functional experiments showed that
upregulation of miR-100 could inhibit growth of NSCLC
cells, which might be apoptosis enhancement and cell cycle
arrest in G2/M stage. Sequence analyses revealed that the
3’-UTR of PLK1 mRNA contains a putative site partially
complementary to miR-100. By firefly luciferase activity
assay, miR-100 could inhibit luciferase activity in the PLK1
WT but had no effect in the mutant construct. Meanwhile,
miR-100 mimics or inhibitor could lead to the decreased or
increased PLK1 expression in NSCLC at both transcrip-
tional and translational levels. By functional analysis, it was
shown that siRNA-mediated PLK1 downregulation could
mimic the effects of miR-100 mimics on phenotypes of
NSCLC cells and overexpression of PLK1 could partially re-
verse miR-100 mimics-induced phenotypical changes in
NSCLC cells. Additionally, miR-100 expression was in-
versely correlated with PLK1 mRNA expression in NSCLC
tissues. From these data, PLK1 is a direct and functional
target gene in NSCLC. While a single miRNA can target
many genes, multiple miRNAs can regulate a single gene.
In acute myeloid leukemia, RBSP3 (a phosphatase-like
tumor suppressor) has been validated as a bona fide target
of miR-100 [37]. Zheng and his colleagues revealed a
new pathway that miR-100 regulates G1/S transition and
S-phase entry and blocks the terminal differentiation by tar-
geting RBSP3, which promoted cell proliferation. However,
the functions of RBSP3 and its correlation with posttran-
scriptional regulation of miR-100 in NSCLC are unclear
and remains to be elucidated in future research.
Conclusions
Our results showed that low miR-100 might be a poor
prognostic factor for NSCLC patients. As the number of
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larger case population is necessary to confirm the clin-
ical significance of miR-100 expression in NSCLC. Also,
overexpression of miR-100 could inhibit growth, en-
hance apoptosis and induce cell cycle arrest in G2/M
stage, which is possibly owing to increased apoptosis
associated with downregulation of PLK1 expression.
This raises the possibility that anti-miR-100 may have
potential therapeutic value for NSCLC. While the goal
of this study was to better understand miR-100 function
in NSCLC, future research is required to address the
therapeutic potential of modulating miR-100.
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